These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 31853597)
1. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Bhide AA; Tailor V; Fernando R; Khullar V; Digesu GA Int Urogynecol J; 2020 May; 31(5):865-870. PubMed ID: 31853597 [TBL] [Abstract][Full Text] [Related]
2. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children. Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257 [TBL] [Abstract][Full Text] [Related]
3. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786 [TBL] [Abstract][Full Text] [Related]
4. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. Ridout AE; Yoong W J Obstet Gynaecol; 2010 Feb; 30(2):111-4. PubMed ID: 20143965 [TBL] [Abstract][Full Text] [Related]
5. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. Martinson M; MacDiarmid S; Black E J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264 [TBL] [Abstract][Full Text] [Related]
6. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment? Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823 [TBL] [Abstract][Full Text] [Related]
7. Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices. Lee UJ; MacDiarmid S; Matthews CA; Gillespie E; Peters KM Adv Ther; 2024 Jul; 41(7):2635-2654. PubMed ID: 38748331 [TBL] [Abstract][Full Text] [Related]
8. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541 [TBL] [Abstract][Full Text] [Related]
9. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin? Tubaro A; Puccini F; De Nunzio C Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873 [TBL] [Abstract][Full Text] [Related]
10. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Tudor KI; Seth JH; Liechti MD; Ochulor J; Gonzales G; Haslam C; Fox Z; Pakzad M; Panicker JN Clin Auton Res; 2020 Feb; 30(1):61-67. PubMed ID: 30074101 [TBL] [Abstract][Full Text] [Related]
11. Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications. Te Dorsthorst M; van Balken M; Heesakkers J Curr Opin Urol; 2020 Jul; 30(4):513-518. PubMed ID: 32452995 [TBL] [Abstract][Full Text] [Related]
12. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542 [TBL] [Abstract][Full Text] [Related]
13. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. Peters KM; Carrico DJ; Perez-Marrero RA; Khan AU; Wooldridge LS; Davis GL; Macdiarmid SA J Urol; 2010 Apr; 183(4):1438-43. PubMed ID: 20171677 [TBL] [Abstract][Full Text] [Related]
14. [Neuromodulation as a treatment for overactive bladder syndrome]. Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803 [TBL] [Abstract][Full Text] [Related]
15. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection? Zahner PM; Giusto LL; Goldman HB Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438 [TBL] [Abstract][Full Text] [Related]